What is the recommended dosing schedule for sucralfate (Carafate) in adults and children, and are any dose adjustments needed for renal or hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Carafate (Sucralfate) Dosing

The standard adult dose of sucralfate is 1 gram four times daily on an empty stomach, taken 1 hour before meals and at bedtime, for 4-8 weeks in active duodenal ulcer disease 1.

Adult Dosing

Standard Regimen

  • Active duodenal ulcer: 1 gram four times daily (1 hour before meals and at bedtime) 1
  • Treatment duration: 4-8 weeks unless healing is demonstrated earlier by endoscopy or x-ray 1
  • Administration: Must be taken on an empty stomach 1

Alternative Regimen

A more convenient twice-daily dosing of 2 grams twice daily (upon waking and at bedtime) is equally effective and may improve adherence 2, 3. Studies demonstrate healing rates of 79% at 4 weeks and 85% at 8 weeks with this regimen, comparable to the four-times-daily schedule 2.

Maintenance Therapy

  • Dose: 1 gram twice daily for prevention of ulcer relapse 3
  • Alternative: 1 gram in morning and 2 grams at bedtime for gastric ulcer prevention 3
  • Efficacy: Reduces relapse rate from 60% to 20% at 6 months and from 81% to 30% at 1 year 3

Pediatric Dosing

No specific pediatric dosing is established in the FDA label 1. The drug should be used with caution in children, and prescribing information recommends careful consideration before use in pediatric patients 1.

Dose Adjustments

Renal Impairment

Sucralfate should be used with extreme caution or avoided in chronic renal failure 1, 4. Key considerations:

  • Only 3-5% of sucralfate is absorbed systemically, but the aluminum component accumulates significantly in renal impairment 5, 4
  • In chronic renal insufficiency, serum aluminum levels increase substantially (from 0.11 to 0.83 μmol/L after 22 days) with elimination half-life of 13.1 days 4
  • Patients on dialysis are at highest risk for aluminum accumulation, as aluminum does not cross dialysis membranes 1, 6
  • In critically ill children with acute renal failure receiving peritoneal dialysis, median aluminum levels reached 2.86 μmol/L (range 0.19-12.3) versus 0.55 μmol/L in non-dialyzed patients 6
  • If sucralfate must be used in renal failure, serum aluminum concentrations require regular monitoring 6

Hepatic Impairment

No dose adjustment is required for hepatic impairment 1. Sucralfate acts locally in the gastrointestinal tract with minimal systemic absorption, and hepatic metabolism is not a significant elimination pathway 5.

Elderly Patients

Dose selection should be cautious, typically starting at the low end of the dosing range (1 gram four times daily), reflecting the greater frequency of decreased renal, hepatic, or cardiac function in this population 1.

Important Drug Interactions

Sucralfate must be separated from other medications by at least 2 hours to avoid binding interactions in the GI tract 1. Critical interactions include:

  • Warfarin: Even with 12-hour separation, sucralfate can significantly reduce warfarin absorption, approximately doubling warfarin requirements and causing subtherapeutic INRs 7. Close INR monitoring is essential.
  • Other affected drugs: cimetidine, digoxin, fluoroquinolones, ketoconazole, levothyroxine, phenytoin, quinidine, ranitidine, tetracycline, theophylline 1
  • Antacids: May be used for pain relief but should not be taken within 30 minutes before or after sucralfate 1

Special Populations

Diabetic Patients

Episodes of hyperglycemia have been reported; close glycemic monitoring is recommended, and antidiabetic medication doses may require adjustment 1.

Pregnancy and Lactation

  • Pregnancy Category B: No evidence of fetal harm in animal studies, but use only if clearly needed 1
  • Lactation: Unknown if excreted in breast milk; use with caution 1

Common Pitfalls

  1. Aluminum toxicity in renal failure: The most serious concern—avoid long-term use or monitor aluminum levels closely 1, 4, 6
  2. Drug interactions: Failure to separate administration by 2 hours can lead to treatment failures, particularly with warfarin, antibiotics, and thyroid medications 1, 7
  3. Inadequate treatment duration: Stopping before 4 weeks may result in incomplete healing 1
  4. Timing with meals: Taking with food reduces efficacy—must be on empty stomach 1

References

3
Research

The efficacy, safety and dosage of sucralfate in ulcer therapy.

Scandinavian journal of gastroenterology. Supplement, 1987

6
Research

Aluminum accumulation in critically ill children on sucralfate therapy.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2001

Related Questions

What is the appropriate dose of sucralfate for an adult?
What are the indications, dosing regimen, administration guidelines, and contraindications for sucralfate in adult and pediatric patients?
What short‑term dosing and monitoring recommendations for Carafate (sucralfate) should be used in an adult with acute peptic ulcer disease or mild gastro‑esophageal reflux who has no hypersensitivity, no severe renal impairment, and is not taking other aluminum‑containing antacids?
What is the recommended loading dose and continuous infusion rate for an aminophylline drip in adult patients, and how should the rate be adjusted for hepatic or renal impairment?
In an adult with acute mild-to-moderate gastroenteritis, is sucralfate indicated, and what is the appropriate dosage and precautions?
What carvedilol dose should be used for a patient with bothersome palpitations and a normal Holter rhythm?
In a patient with recurrent urinary tract infections who is currently receiving ertapenem (1 g intravenous daily) based on susceptibility testing, with no kidney stones on computed tomography and a pending post‑void residual measurement, what is the optimal management plan?
What is the likely cause and recommended evaluation and treatment for tinnitus that worsens when lying on my side and is associated with reduced appetite?
What are the indications and proper usage of triple‑antibiotic ointment (bacitracin, neomycin, polymyxin B) and Santyl (collagenase)?
Can mild hypercalcemia cause seizures?
Can Santyl (collagenase) ointment be used together with triple‑antibiotic ointment (bacitracin‑neomycin‑polymyxin B) on a clean, non‑infected wound in a patient without allergies to these agents?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.